P38 inhibitors and methods of use thereof

Details P38 inhibitors and methods of use thereof P38 inhibitors and methods of use thereof

2006-11-14

2006-11-14

Saeed, Kamal A. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07135575

ABSTRACT:
This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.

REFERENCES:
patent: 5945418 (1999-08-01), Bemis et al.
patent: 6080763 (2000-06-01), Regan et al.
patent: 6093742 (2000-07-01), Salituro et al.
patent: 6214830 (2001-04-01), Beers et al.
patent: 6228881 (2001-05-01), Regan et al.
patent: 6242453 (2001-06-01), Cirillo et al.
patent: 6297381 (2001-10-01), Cirillo et al.
patent: 6358945 (2002-03-01), Breitfelder et al.
patent: 6432995 (2002-08-01), Hickey et al.
patent: 6479507 (2002-11-01), Cheng et al.
patent: 6503930 (2003-01-01), Hanson et al.
patent: 2004/0192653 (2004-09-01), Munson et al.
patent: WO 97/12876 (1997-04-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 01/02369 (2001-01-01), None
patent: WO 02/42292 (2002-05-01), None
patent: WO 02/072579 (2002-09-01), None
patent: WO 2002100833 (2002-12-01), None
patent: WO 03/032989 (2003-04-01), None
patent: WO 03/051847 (2003-06-01), None
* WO 2002100833 is not provided as it is not used in a rejection against applicants' claims and only cited as closest prior art.
Jeffrey C Boehm & Jerry L Adams, “New inhibitors of p38 kinase, Monthly Focus: Pulmonary-Allergy, Dermatological, Gastrointestional & Arthritis,” 2000, pp. 25-37.
Raymond J. Owens and Simon Lumb, “Therapeutic regulation of cytokine signalling by inhibitors of p38 mitogen-activated protein kinase,” Novel Cytokine Inhibitors, Ed. Gerry A. Higgs. and Brian Henderson, 2000, pp. 201-211.
Salituro, E.G., et al. “Inhibitors of p38 MAP Kinas: Therapeutic Intervention in Cytokine-Mediated Diseases,” Current Medicinal Chemistry, 1999, 607-823.
Foster, M.L., et al., “Potential of p38 Inhibitors in the Treatment of Rheumatoid Arthritis,” Drug News Perspect 13 (8), Oct. 2000. pp. 488-496.
Boehm, J.D. and Adams, J.L. “Expert Opinion on Therapeutic Patents,” 10:25-37 (2000).
Natarajan, Swaminathan R., et al. “P38 MAP Kinase Inhibitors. Part 1: Design and Development of a New Class of Potent and Highly Selective Inhibitors Based on 3,4-Dihydropyrido, [3,2-d 1 Pyrimidone Scaffold,” Bioganic & Medicinal Chemistry Letters 13:273-276 (2003).
Judith Branger, et al., “Anti-Imfammatory Effects of a p38 Mitogen-Activiated Protein Kinas Inhibitor During Human Endotoxemia,”1Journal of Immunology 168: 4070-4077 (2002).
PCT Search Report mailed Sep. 1, 2004 in PCT/US04/05693.
Database CAS ONLINE on STN, Chem. Abstr. Accession No. 2002:964330, “Preparation of heterocyclic compounds as Rho-kinase inhibitors”. WO 2002100844 A1 (Sumitomo Pharmaceuticals Company, Limited, Japan) Dec. 19, 2002, abstract.

Affiliated with

Also associated with

Rating

P38 inhibitors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with P38 inhibitors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P38 inhibitors and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3658747